Europe – Novavax: COVID-19 vaccine over 96% effective in UK trial

Trials in the U.S. continue and are expected to be finished in the spring.

The Maryland-based biotech company Novavax reported Thursday that its experimental Covid-19 vaccine is more than 96 percent effective in preventing mild and severe illness.

The results are from the company’s Phase 3 clinical trial, which was conducted in the U.K. Novavax’s trials in the U.S. and South Africa continue, and the company cannot apply for emergency use authorization in the U.S. until the American trials are complete…